Operational tolerance after liver transplantation

Journal of Hepatology

Volumn 50, Issue 6, 2009, Pages 1247-1257

  Orlando, Giuseppe ^a,b   Soker, Shay ^b   Wood, Kathryn ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical operational tolerance; Immunosuppression; Liver transplantation

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; CLINICAL OPERATIONAL TOLERANCE; CLINICAL TRIAL; DNA POLYMORPHISM; DONOR SELECTION; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; LIVER GRAFT; LIVER TRANSPLANTATION; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; RETRANSPLANTATION;

ADULT; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; TISSUE DONORS;

EID: 67349182474     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.03.006     Document Type: Article

References (61)

1. Merrill J.P., Murray J.E., and Harrison J.H. Successful homotransplantation of the human kidney between identical twins. JAMA 160 (1956) 277-282
2. Billingham R.E., Brent L., and Medawar P.B. Actively acquired tolerance of foreign cells. Nature 172 (1953) 603-606
3. Ashton-Chess J., Giral M., Brouard S., and Soulillou J.P. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation 84 (2007) 1215-1219
4. Starzl T.E., Demetris A.J., Trucco M., Murase N., Ricordi C., Ildstad S., et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 17 (1993) 1127-1152
5. Reyes J., Zeevi A., Ramos H., Tzakis A., Todo S., Demetris A.J., et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 25 (1993) 3315-3319
6. Mazariegos G.V., Ramos H., Shapiro R., Zeevi A., Fung J.J., and Starzl T.E. Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study. Transpl Proc 27 (1995) 207-209
7. Ramos H.C., Reyes J., Abu-Elmagd K., Zeevi A., Reinsmoen N., Tzakis A., et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 59 (1995) 212-217
8. Mazariegos G.V., Reyes J., Marino I.R., Demetris A.J., Flynn B., Irish W., et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 63 (1997) 243-249
9. Tzakis A.G., Reyes J., Zeevi A., Ramos H., Nour B., Reinsmoen N., et al. Early tolerance in pediatric liver allograft recipients. J Pediatr Surg 29 (1994) 754-756
10. Mazariegos G.V., Sindhi R., Thomson A.W., and Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol 17 (2007) 114-119
11. Thomson A.W., Mazariegos G.V., Reyes J., Donnenberg V.S., Donnenberg A.D., Bentlejewski C., et al. Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients. Transplantation 72 8 Suppl (2001) S13-S22
12. Mazariegos G.V., Zahorchak A.F., Reyes J., Ostrowski L., Flynn B., Zeevi A., et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 3 (2003) 689-696
13. Mazariegos G.V., Zahorchak A.F., Reyes J., Chapman H., Zeevi A., and Thomson A.W. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 5 (2005) 314-322
14. Tokita D., Mazariegos G.V., Zahorchak A.F., Chien N., Abe M., Raimondi G., et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 85 (2008) 369-377
15. Devlin J., Doherty D., Thomson L., Wong T., Donaldson P., Portmann B., et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 27 (1998) 926-933
16. Girlanda R., Rela M., Williams R., O'Grady J.G., and Heaton N.D. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 37 (2005) 1708-1709
17. VanBuskirk A.M., Burlingham W.J., Jankowska-Gan E., Chin T., Kusaka S., Geissler F., et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 106 (2000) 145-155
18. Geissler F., Jankowska-Gan E., DeVito-Haynes L.D., Rhein T., Kalayoglu M., Sollinger H.W., et al. Human liver allograft acceptance and the "tolerance assay: in vitro anti-donor T cell assays show hyporeactivity to donor cells, but unlike DTH, fail to detect linked suppression. Transplantation 72 (2001) 571-580
19. Wood K.J., and Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3 (2003) 199-210
20. Takatsuki M., Uemoto S., Inomata Y., Sakamoto S., Hayashi M., Ueda M., et al. Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance. Transpl Immunol 8 (2001) 279-286
21. Takatsuki M., Uemoto S., Inomata Y., Egawa H., Kiuchi T., Fujita S., et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 72 (2001) 449-454
22. Koshiba T., Li Y., Takemura M., Wu Y., Sakaguchi S., Minato N., et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 17 (2007) 94-97
23. Li Y., Koshiba T., Yoshizawa A., Yonekawa Y., Masuda K., Ito A., et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 4 (2004) 2118-2125
24. Yoshizawa A., Ito A., Li Y., Koshiba T., Sakaguchi S., Wood K.J., et al. The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc 37 (2005) 37-39
25. Pons J.A., Yélamos J., Rami{dotless}́rez P., Oliver-Bonet M., Sánchez A., Rodri{dotless}́guez-Gago M., et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 75 (2003) 1045-1047
26. Tisone G., Orlando G., and Angelico M. Operational tolerance in clinical liver transplantation: emerging developments. Transpl Imm 17 (2007) 108-113
27. Tisone G., Orlando G., Cardillo A., Palmieri G., Manzia T.M., Baiocchi L., et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 44 (2006) 702-709
28. Orlando G., Manzia T., Baiocchi L., Sanchez-Fueyo A., Angelico M., and Tisone G. The Tor Vergat Weaning Off Immunosuppression Trial in HCV liver transplant patients. The updated follow up at 78 months. Transpl Imm 20 (2008) 43-47
29. Karam V.H., Gasquet I., Delvart V., Hiesse C., Dorent R., Danet C., et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 76 (2003) 1699-1704
30. Gras J., Wieërs G., Vaerman J.L., Truong D.Q., Sokal E., Otte J.B., et al. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl 13 (2007) 426-433
31. Hsu L.W., Goto S., Nakano T., Lai C.Y., Lin Y.C., Kao Y.H., et al. Immunosuppressive activity of serum taken from a liver transplant recipient after withdrawal of immunosuppressants. Transpl Immunol 17 (2007) 137-146
32. Alexander S.I., Smith N., Hu M., Verran D., Shun A., Dorney S., et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 358 (2008) 369-374
33. Starzl T.E., Murase N., Abu-Elmagd K., Gray E.A., Shapiro R., Eghtesad B., et al. Tolerogenic immunosuppression for organ transplantation. Lancet 361 (2003) 1502-1510
34. Trzonkowski P., Zilvetti M., Chapman S., Wieckiewicz J., Sutherland A., Friend P., et al. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 8 (2008) 338-347
35. Watson C.J., Bradley J.A., Friend P.J., Firth J., Taylor C.J., Bradley J.R., et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 5 (2005) 1347-1353
36. Knechtle S.J., Fernandez L.A., Pirsch J.D., Becker B.N., Chin L.T., Becker Y.T., et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 136 (2004) 754-760
37. Agarwal A., Shen L.Y., and Kirk A.D. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. Transpl Immunol 20 (2008) 6-11
38. Kirk A.D., Hale D.A., Mannon R.B., Kleiner D.E., Hoffmann S.C., Kampen R.L., et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76 (2003) 120-129
39. Ciancio G., and Burke III G.W. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 8 (2008) 15-20
40. Eason J.D., Cohen A.J., Nair S., Alcantera T., and Loss G.E. Tolerance: is it worth the risk?. Transplantation 79 (2005) 1157-1159
41. Trzonkowski P., Zilvetti M., Friend P., and Wood K.J. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation 82 (2006) 1342-1351
42. Pearl J.P., Parris J., Hale D.A., Hoffmann S.C., Bernstein W.B., McCoy K.L., et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5 (2005) 465-474
43. Assy N., Adams P.C., Myers P., Simon V., Minuk G.Y., Wall W., et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation 83 (2007) 1571-1576
44. Assy N., Adams P.C., Myers P., Simon V., and Ghent C.N. A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. Gut 56 (2007) 304-306
45. Persson H., Friman S., Scherstén T., Svanvik J., and Karlberg I. Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients. Lancet 336 (1990) 52-53
46. Matthes-Martin S., Peters C., Königsrainer A., Fritsch G., Lion T., Heitger A., et al. Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood 96 (2000) 3997-3999
47. Mellgren K., Fasth A., Saalman R., Olausson M., and Abrahamsson J. Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia. Ann Hematol 84 (2005) 755-757
48. Donckier V., Troisi R., Toungouz M., Colle I., Van Vlierberghe H., Jacquy C., et al. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl Immunol 13 (2004) 139-146
49. Donckier V., Troisi R., Le Moine A., Toungouz M., Ricciardi S., Colle I., et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl 12 (2006) 1523-1528
50. Craciun L., Stordeur P., Troisi R., Le Moine A., Toungouz M., Colle I., et al. A rapid test of alloreactivity based on interleukin-2 mRNA expression might identify liver transplant recipients with donor-specific hyporesponsiveness. Transplant Proc 39 (2007) 2665-2667
51. Tryphonopoulos P., Tzakis A.G., Weppler D., Garcia-Morales R., Kato T., Madariaga J.R., et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 5 (2005) 608-613
52. Mathew J.M., Garcia-Morales R.O., Carreno M., Jin Y., Fuller L., Blomberg B., et al. Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transpl Immunol 11 (2003) 307-321
53. Monaco A.P., and Wood M.L. Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc 2 (1970) 489-496
54. Hematti P. Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev (Orlando) 22 (2008) 262-273
55. Le Blanc K., and Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262 (2007) 509-525
56. Kawai T., Cosimi A.B., Spitzer T.R., Tolkoff-Rubin N., Suthanthiran M., Saidman S.L., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. NEJM 358 (2008) 353-361
57. Urban C.H., Deutschmann A., Kerbl R., Lackner H., Schwinger W., Königsrainer A., et al. Organ tolerance following cadaveric liver transplantation for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 30 (2002) 535-537
58. Kadry Z., Mullhaupt B., Renner E.L., Bauerfeind P., Schanz U., Pestalozzi B.C., et al. Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. Transplantation 76 (2003) 1003-1006
59. Andreoni K.A., Lin J.I., and Groben P.A. Liver transplantation 27 years after bone marrow transplantation from the same living donor. N Engl J Med 350 (2004) 2624-2625
60. Marti{dotless}́nez-Llordella M., Lozano J.J., Puig-Pey I., Orlando G., Tisone G., Lerut J., et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 118 (2008) 2845-2857
61. Marti{dotless}́nez-Llordella M., Puig-Pey I., Orlando G., Tisone G., Ramoni M., Lerut J., et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transpl 7 (2007) 309-319